Tr1X

Tr1X is pioneering a new category of cell therapy focused on immune regulation rather than immune destruction. The company leverages deep immunology expertise and genetic engineering to create stable, scalable Tr1 cell therapies designed to home to sites of inflammation and induce long-term tolerance. With its lead program, TRX103, already demonstrating initial clinical proof of safety and mechanism in GvHD, Tr1X is advancing a multi-program pipeline targeting major autoimmune conditions like Crohn's disease and multiple sclerosis.

Genetic engineering platform to create allogeneic, off-the-shelf Type 1 regulatory T (Tr1) cells. Engineered for targeted homing to inflammation, localized cytokine suppression, high stability in inflammatory environments, and induction of new host Tr1 cells to restore immune tolerance.

Tr1X operates in the emerging competitive field of engineered regulatory T cell therapies. Key competitors include companies like GentiBio, Abata Therapeutics (backed by Third Rock), Sangamo Therapeutics, and TxCell. It also faces indirect competition from developers of other immunomodulatory biologics, small molecules, and autologous cell therapies. Tr1X differentiates with its specific focus on the Tr1 cell subset and its platform designed for stability and de-novo Treg induction.